As a new-type foreign trade service provider driven by technological transformation and foreign trade business, HiSiaddi has established a "1+2+3+4=1" service system and can supply DBS dibutyl sebacate from multiple well-known original manufacturers. As a tech-driven foreign trade service provider, HiSiaddi repeatedly delivers DBS dibutyl sebacate formulation optimization schemes and application improvement suggestions relying on technological transformation cooperation with factories and precise market demand insights. Below is a consulting case of DBS dibutyl sebacate formulation optimization by HiSiaddi. Contact HiSiaddi customer service for more formulation optimization consulting services.
End Buyer: FINMED OY, Finland A mid-to-high-end Nordic medical terminal manufacturer, not an intermediary trader. Located in the biomedicine industrial park of Helsinki, Finland, FINMED OY has 35 years of R&D and production experience in sterile medical infusion hoses, disposable blood collection device sheaths, and low-temperature medical & food composite films. Its products supply public hospitals across Nordic countries and renowned food processing groups, complying with EU 10/2011 food contact regulations, USP pharmaceutical excipient standards, REACH, and RoHS directives. The original low-temperature plasticizing system adopted BASF Germany pharmaceutical-grade DBS as the primary plasticizer with an annual DBS consumption of 132 tons. The PVC formulation matched with imported DBS had undergone years of mass-production optimization, delivering stable low-temperature toughness, high-temperature sterilization stability, and anti-precipitation performance with a permanent finished product yield above 99.7%. Amid rising prices of European vegetable oils and fine chemicals, maintenance shutdowns of overseas chemical plants, and extended import lead time to 105 days, the client aimed to cut procurement costs and shorten delivery cycles by independently sourcing 28 tons of domestic national standard food-grade general DBS from two Chinese manufacturers. The client directly adopted the original formulation ratios, mixing temperature controls, and extrusion processes tailored for BASF raw materials across four automated production lines. Within 10 days of production, three fatal manufacturing defects emerged: oil blooming on the inner wall of medical tubes after one week of ambient storage, tube whitening and turbidity post 121°C autoclave sterilization, and mass cracking after bending under -38°C Nordic cold-chain storage. A total of 4.9 tons of semi-finished products failed inspection, prompting downstream pharmaceutical clients to suspend incoming material acceptance. Delayed delivery would incur substantial liquidated damages. Domestic DBS manufacturers only handle raw material synthesis and production without downstream medical PVC formulation R&D capabilities. Eight rounds of adjustments to DBS dosage failed to eliminate defects, trapping the client in a dilemma: higher dosage causes precipitation while lower dosage leads to rigid tubes. FINMED OY urgently commissioned HiSiaddi to form a special technical team to systematically resolve the technical issues via four dimensions: raw material performance testing traceability, defect mechanism analysis, formulation system optimization, and workshop extrusion process rectification.
The mature original formulation was benchmarked on 100 PHR PVC with a BASF DBS loading of 27 PHR. Direct equal dosing of domestic raw materials triggered three defects exceeding internal acceptance standards:
1. Oil blooming and precipitation on inner tube walls: After 7 days of sealed storage, oily precipitates appeared on tube inner walls. Trace plasticizer migrated and dissolved upon contact with medicinal liquids, violating USP medical extractable substance control standards. Specific DBS migration exceeded legal limits in four EU 10/2011 food simulant tests.
2. Tube whitening and turbidity post high-temperature sterilization: After 30 minutes of 121°C steam sterilization, haze of transparent tubes surged with light transmittance dropping by 22%, failing medical consumable appearance and functional specifications.
3. Brittle cracking under ultra-low temperature bending: After 72 hours static storage at -38°C, tubes cracked after 1,500 repeated bends, while original BASF samples remained intact after 20,000 bends under identical conditions, rendering products unfit for Nordic cold storage and clinical low-temperature applications. HiSiaddi’s technical team collected full sets of raw materials including original BASF DBS, delivered domestic DBS, client PVC resin, calcium-zinc stabilizers, and epoxidized soybean oil for parallel testing at an SGS laboratory with EU accreditation in China, identifying three root causes of defects:
① Domestic DBS main ester content stands at 99.1% versus ≥99.8% for BASF refined grades. High residual unesterified sebacic acid, free n-butanol, and small-molecule monoester impurities show poor compatibility with PVC, migrating out of the substrate during long-term storage to form blooming deposits. This is the core cause of precipitation. ② Domestic DBS acid value reaches 0.07 mgKOH/g, far exceeding BASF’s 0.025 mgKOH/g. Acidic impurities damage the calcium-zinc thermal stabilization system during high-temperature sterilization, triggering minor PVC degradation to form microcrystalline spots and tube whitening/turbidity. ③ Irregular isomer ratios with a high proportion of high-freezing-point components reduce molecular chain flexibility at low temperatures. Single dosing drastically weakens PVC low-temperature toughness and induces cold cracking.
Polarity and solubility of all auxiliary agents in the original formulation were matched to high-purity imported DBS. Equal 27 PHR dosing of lower-polarity domestic DBS exceeded the safe compatibility limit. Original epoxidized soybean oil and lubricant ratios formulated for imported DBS created excessive lubrication when blended with domestic DBS, accelerating plasticizer migration and blooming.
BASF DBS boasts superior thermal stability, supporting the original mixing final temperature of 130°C and extrusion zone temperatures of 165–182°C. Domestic DBS exhibits weaker heat resistance; high-temperature processing accelerates small-molecule impurity volatilization and degradation, worsening precipitation and tube haze.
HiSiaddi coordinated suppliers to optimize synthesis and rectification processes: replace sulfuric acid catalysts with eco-friendly solid acid systems and install secondary high-vacuum rectification to remove small-molecule by-products, finalizing a dedicated FM-DBS medical modified grade exclusively for FINMED OY. Modified DBS delivers main ester ≥99.7%, acid value ≤0.03 mgKOH/g, and thermal weight loss ≤0.3%. For the existing 28 tons of general-grade DBS inventory, the client was guided to conduct 24-hour sealed constant-temperature pretreatment at 50°C to reduce raw material viscosity, improve PVC adsorption and fusion efficiency, and mitigate poor mixing dispersion.
Original Formulation: 100 PVC + 27 DBS + 4.0 calcium-zinc stabilizer + 3.8 ESBO + 1.5 internal & external lubricant Optimized Formulation: 100 PVC + 22 modified DBS + 5 food-grade ATBC + 4.5 high-efficiency low-zinc calcium-zinc stabilizer + 4.2 epoxidized soybean oil + 0.9 low-precipitation composite lubricant Optimization Logic:
1. Reduce DBS loading from 27 PHR to 22 PHR, compound with 5 PHR ATBC citrate plasticizer. ATBC’s superior compatibility locks free small molecules to fundamentally eliminate blooming and migration.
2. Increase calcium-zinc stabilizer dosage to neutralize trace free acid in DBS; paired with epoxy groups in ESBO to capture hydrogen chloride released during PVC thermal degradation and prevent tube whitening from PVC degradation during sterilization.
3. Cut external lubricant dosage and adopt a low-migration lubrication system to avoid lubricant overflow carrying DBS and causing precipitation. Small amounts of low-temperature resistant DOA may be compounded for enhanced low-temperature performance if required.
1. Adjust feeding sequence and mixing parameters: Pre-mix PVC alone for 2 minutes → sequentially feed stabilizers, ESBO, and processing aids for compounding → slowly add preheated DBS at uniform speed. Lower hot mixing termination temperature from 130°C to 118°C to fully discharge volatile raw material impurities, with cold mixing discharge temperature ≤42°C.
2. Lower overall extruder zone temperatures by 5–7°C: Zone 1 barrel 158°C, Zone 2 163°C, Zone 3 169°C, die head 175°C to reduce small-molecule decomposition and volatilization of DBS induced by high heat. Cut screw speed by 7% to extend material plasticization residence time and boost fusion between plasticizer and resin.
Optimized formulation samples were sent to Finnish laboratories for full simulation sterilization, low-temperature, and migration testing. Tubes showed no blooming, maintained transparency post sterilization without whitening, and resisted cracking after 20,000 bends at -38°C, with all indicators matching original BASF products and complying with USP and EU 10/2011 regulations.
New formulations and processes were fully implemented on one production line, delivering continuous production without die cleaning shutdowns. Finished products passed all tests at Finland’s national food & drug testing institute, lifting yield from 63.2% pre-rectification to 99.85%. The remaining three production lines switched processes in batches, fully consuming the 28-ton raw material inventory and fulfilling backlogged orders on schedule.
Monthly shipments of the FM-DBS modified grade split into 11 batches per year. Compared with imported BASF raw materials, overall procurement costs decreased by 30.2%, and delivery lead time shortened from 105 days to 33 days.
1. Full-category auxiliary agent technical trusteeship: FINMED OY launched a new low-temperature food packaging project and entrusted HiSiaddi with permanent technical trusteeship for localization selection and formulation testing of all plasticizers including DBS, ESBO, and ATBC. Pre-shipment compatibility testing of raw materials eliminates production failures.
2. Standardized export grade finalized by manufacturers: Leveraging Finnish medical production test data, the supplier formalized the FM-DBS Nordic medical exclusive grade, supplemented with full REACH and EU 10/2011 compliance documentation. HiSiaddi secured customized orders from two equivalent medical plastic manufacturers in Sweden and Norway.
3. Client establishment of raw material incoming inspection protocols: HiSiaddi assists full physical & chemical and migration testing of all domestic DBS deliveries prior to production authorization.
1. Industry Pain Points: Domestic DBS manufacturers prioritize mass production of national standard general-grade products, only controlling basic national standard physical & chemical indicators without downstream medical PVC formulation R&D capabilities. European and American mid-to-high-end medical enterprises finalize formulations around imported refined DBS; direct equal replacement with domestic general-grade materials easily triggers compatibility imbalance and mass product scrap.
2. Core Value of HiSiaddi: Forms a full technical closed loop covering raw material defect diagnosis, grade improvement, formulation reconstruction, and production process implementation, bridging the application technology gap between raw material manufacturers and overseas end manufacturers.
Procurement Logic of High-end Clients: Nordic mid-to-high-end medical clients prioritize product stability, supporting formulation & process services, and compliance capacity, accepting moderate premiums for improved grades. End-to-end technical support is the key to locking long-term cooperation. Contact HiSiaddi customer service for more formulation optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
